145 related articles for article (PubMed ID: 28286613)
1. Treatment Outcomes and Clinicopathologic Characteristics of Triple-Negative Breast Cancer: A Report from Cancer Institute of Iran.
Mirzania M; Safaee SR; Shahi F; Jahanzad I; Zahedi G; Mehdizadeh R
Int J Hematol Oncol Stem Cell Res; 2017 Jan; 11(1):37-42. PubMed ID: 28286613
[No Abstract] [Full Text] [Related]
2. c-Met and ERβ expression differences in basal-like and non-basal-like triple-negative breast cancer.
Ren X; Yuan L; Shen S; Wu H; Lu J; Liang Z
Tumour Biol; 2016 Aug; 37(8):11385-95. PubMed ID: 26968553
[TBL] [Abstract][Full Text] [Related]
3. Comparison of Clinicopathological Features and Prognosis in Triple-Negative and Non-Triple Negative Breast Cancer.
Qiu J; Xue X; Hu C; Xu H; Kou D; Li R; Li M
J Cancer; 2016; 7(2):167-73. PubMed ID: 26819640
[TBL] [Abstract][Full Text] [Related]
4. Immunohistochemical co-expression status of cytokeratin 5/6, androgen receptor, and p53 as prognostic factors of adjuvant chemotherapy for triple negative breast cancer.
Maeda T; Nakanishi Y; Hirotani Y; Fuchinoue F; Enomoto K; Sakurai K; Amano S; Nemoto N
Med Mol Morphol; 2016 Mar; 49(1):11-21. PubMed ID: 26009308
[TBL] [Abstract][Full Text] [Related]
5. Clinicopathological characteristics of triple negative breast cancer at a tertiary care hospital in India.
Dogra A; Doval DC; Sardana M; Chedi SK; Mehta A
Asian Pac J Cancer Prev; 2014; 15(24):10577-83. PubMed ID: 25605142
[TBL] [Abstract][Full Text] [Related]
6. Stratification of Prognosis of Triple-Negative Breast Cancer Patients Using Combinatorial Biomarkers.
Yue Y; Astvatsaturyan K; Cui X; Zhang X; Fraass B; Bose S
PLoS One; 2016; 11(3):e0149661. PubMed ID: 26930401
[TBL] [Abstract][Full Text] [Related]
7. Clinicopathological Study of Triple Negative Breast Cancers.
Ishitha G; Manipadam MT; Backianathan S; Chacko RT; Abraham DT; Jacob PM
J Clin Diagn Res; 2016 Sep; 10(9):EC05-EC09. PubMed ID: 27790442
[TBL] [Abstract][Full Text] [Related]
8. Clinicopathological, therapeutic and prognostic features of the triple-negative tumors in moroccan breast cancer patients (experience of Hassan II university hospital in Fez).
Akasbi Y; Bennis S; Abbass F; Znati K; Joutei KA; Amarti A; Mesbahi OE
BMC Res Notes; 2011 Nov; 4():500. PubMed ID: 22088140
[TBL] [Abstract][Full Text] [Related]
9. Lack of Androgen Receptor Expression Selects for Basal-Like Phenotype and Is a Predictor of Poor Clinical Outcome in Non-Metastatic Triple Negative Breast Cancer.
Riaz N; Idress R; Habib S; Lalani EN
Front Oncol; 2020; 10():1083. PubMed ID: 32850312
[No Abstract] [Full Text] [Related]
10. [Triple-negative breast cancer: analysis of patients diagnosed and/or treated at the Masaryk Memorial Cancer Institute between 2004 and 2009].
Svoboda M; Navrátil J; Fabian P; Palácová M; Gombošová J; Slámová L; Princ D; Syptáková B; Kudláček A; Bílek O; Pospíšil P; Kazda T; Grell P; Poprach A; Selingerová I; Nenutil R; Juráček J; Héžová R; Slabý O; Vyzula R
Klin Onkol; 2012; 25(3):188-98. PubMed ID: 22724568
[TBL] [Abstract][Full Text] [Related]
11. Clinicopathological comparison of triple negative breast cancers with non-triple negative breast cancers in a hospital in North India.
Nabi MG; Ahangar A; Wahid MA; Kuchay S
Niger J Clin Pract; 2015; 18(3):381-6. PubMed ID: 25772923
[TBL] [Abstract][Full Text] [Related]
12. The role of BRCA1-IRIS in the development and progression of triple negative breast cancers in Egypt: possible link to disease early lesion.
Bogan D; Meile L; El Bastawisy A; Yousef HF; Zekri AN; Bahnassy AA; ElShamy WM
BMC Cancer; 2017 May; 17(1):329. PubMed ID: 28499366
[TBL] [Abstract][Full Text] [Related]
13. Feasibility of Classification of Triple Negative Breast Cancer by Immunohistochemical Surrogate Markers.
Kim S; Moon BI; Lim W; Park S; Cho MS; Sung SH
Clin Breast Cancer; 2018 Oct; 18(5):e1123-e1132. PubMed ID: 29754847
[TBL] [Abstract][Full Text] [Related]
14. Beyond Axillary Lymph Node Metastasis, BMI and Menopausal Status Are Prognostic Determinants for Triple-Negative Breast Cancer Treated by Neoadjuvant Chemotherapy.
Bonsang-Kitzis H; Chaltier L; Belin L; Savignoni A; Rouzier R; Sablin MP; Lerebours F; Bidard FC; Cottu P; Sastre-Garau X; Laé M; Pierga JY; Reyal F
PLoS One; 2015; 10(12):e0144359. PubMed ID: 26684197
[TBL] [Abstract][Full Text] [Related]
15. Clinicopathological features of indonesian breast cancers with different molecular subtypes.
Widodo I; Dwianingsih EK; Triningsih E; Utoro T; Soeripto
Asian Pac J Cancer Prev; 2014; 15(15):6109-13. PubMed ID: 25124582
[TBL] [Abstract][Full Text] [Related]
16. Triple negative breast cancer in people of North East India: critical insights gained at a regional cancer centre.
Sharma M; Sharma JD; Sarma A; Ahmed S; Kataki AC; Saxena R; Sharma D
Asian Pac J Cancer Prev; 2014; 15(11):4507-11. PubMed ID: 24969877
[TBL] [Abstract][Full Text] [Related]
17. Mesothelin expression in triple negative breast carcinomas correlates significantly with basal-like phenotype, distant metastases and decreased survival.
Tozbikian G; Brogi E; Kadota K; Catalano J; Akram M; Patil S; Ho AY; Reis-Filho JS; Weigelt B; Norton L; Adusumilli PS; Wen HY
PLoS One; 2014; 9(12):e114900. PubMed ID: 25506917
[TBL] [Abstract][Full Text] [Related]
18. Differential roles of Bcl2L12 and its short variant in breast cancer lymph node metastasis.
Chien ST; Yang TF; Yang MC; Hsu CM; Hong YR; Lee TM
Oncol Rep; 2015 Aug; 34(2):961-71. PubMed ID: 26082034
[TBL] [Abstract][Full Text] [Related]
19. Pathological Characteristics of Triple-Negative Breast Cancer at Main Referral Teaching Hospital, April 2014 to April 2015, Tehran, Iran.
Abdollahi A; Etemadi M
Int J Hematol Oncol Stem Cell Res; 2016 Oct; 10(4):200-205. PubMed ID: 27928473
[No Abstract] [Full Text] [Related]
20. Comparison of invasive micropapillary and triple negative invasive ductal carcinoma of the breast.
Chen HL; Ding A
Breast; 2015 Dec; 24(6):723-31. PubMed ID: 26392199
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
